Ovarian cancer recurrence combination treatment improves survival
Filed under: Ovarian Cancer, Clinical Trials, Cancer Survivors
I love to write about new studies combining drugs to improve survival of any kind of cancer. When I read these articles I immediately want to write about them. The reason is because having had breast cancer, I’m always afraid of a recurrence. Knowing that new treatment combinations are working, keeps my anxiety at bay.
An article recently published in the Annals of Oncology says that treatment consisting of Doxil and carboplatin may improve survival in patients with relapsed ovarian cancer.
Researchers in France conducted a clinical trial to evaluate Doxil plus carboplatin in the treatment of patients with advanced ovarian cancer that had relapsed following prior platinum and taxane based regimens.
Anticancer responses occurred in 63 percent of patients. Complete disappearances of cancer occurred in 38 percent of patients. The researchers conclude that the combination of Doxil/carboplatin appears highly effective for women with advanced ovarian cancer.
Read | Permalink | Email this | Linking Blogs | Comments
Original post by Kristina Collins
No comments yet. Be the first.
Leave a reply
Ovarian cancer recurrence combination treatment improves survival
Filed under: Ovarian Cancer, Clinical Trials, Cancer Survivors
I love to write about new studies combining drugs to improve survival of any kind of cancer. When I read these articles I immediately want to write about them. The reason is because having had breast cancer, I’m always afraid of a recurrence. Knowing that new treatment combinations are working, keeps my anxiety at bay.
An article recently published in the Annals of Oncology says that treatment consisting of Doxil and carboplatin may improve survival in patients with relapsed ovarian cancer.
Researchers in France conducted a clinical trial to evaluate Doxil plus carboplatin in the treatment of patients with advanced ovarian cancer that had relapsed following prior platinum and taxane based regimens.
Anticancer responses occurred in 63 percent of patients. Complete disappearances of cancer occurred in 38 percent of patients. The researchers conclude that the combination of Doxil/carboplatin appears highly effective for women with advanced ovarian cancer.
Read | Permalink | Email this | Linking Blogs | Comments
Original post by Kristina Collins
No comments yet. Be the first.
Leave a reply






